Osugacestat (AL101, BMS-906024)
Sources
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT03691207
ACCURACY (AL101, osugacestat, gamma secretase inhibitor), NCT03691207, results posted 01.31.2024 (registry; opened 2026-10-27): NOTCH1 to 4 activating mutation required; Cohort 1 AL101 4 mg (n 45) ORR 3 responders, Cohort 2 6 mg (n 42) 2 responders; clinical benefit response 28 and 24 participants; median OS 9.3 months (6.6 to 14.2) and 9.4 months (5.9 to 11.9); serious AEs 23 of 45 and 26 of 42. ESMO 2023 abstract 903P (doi 10.1016/j.annonc.2023.09.2048) and ASCO 2022 abstract 6046 not opened; a 7% discontinuation rate in the search record is not verified. Identification: osugacestat is BMS-906024 (PMC4434460; NCI EVS C116872). AL102 is varegacestat, a different gamma secretase inhibitor for desmoid tumors (Immunome release on the NDA, opened earlier this run).
Brief source A18
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT03691207
A Phase 2, Open-Label, Multi-center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
ClinicalTrials.gov API v2 record, retrieved 2026-11-07